There is one clinical trial.
Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients with COVID-19 (SARS-CoV2) Illness. To evaluate safety and efficacy of a bolus loading dose and continuous intravenous infusion of L-Citrulline compared to placebo in patients hospitalized with COVID-19 infection (SARS-CoV-2).
Description: The primary biochemical objective of this trial is to evaluate the effects of intravenous L-Citrulline on plasma levels of citrulline and arginine in patients admitted to the hospital with COVID-19 infection (SARS-CoV2) and acute hypoxemic respiratory symptoms requiring oxygen therapy. An association of plasma amino acid levels to clinical outcomes may serve as surrogate marker for response. Also measured is time on vent and time in ICU along with hospital stayMeasure: Primary Biochemical Objective to measure levels of citrulline and arginine in the Blood Time: Day 1 through Day 60 Follow up
Description: Hemodynamic measurements will be converted to a vasopressor dependency index (VDI) for analysis through day 10Measure: The primary safety objective is a beneficial effect of intravenous L-Citrulline on hemodynamic status. Time: Day 1 through Day 10
Description: The primary clinical objective is to evaluate the difference in the length of time to an intubation event in hours from the start of study infusion between the study arms.Measure: Primary Clinical Objective Time: Day 1 through day 60 Follow-up
Description: To evaluate the safety of intravenous L-Citrulline compared to placebo as measured by incidence of reported adverse events.Measure: Evaluate the Safety of L-Citrulline Time: Day 1 through Day 60 Follow-up
Description: To evaluate the effect of intravenous L-Citrulline compared to placebo as measured by the total length of all mechanical ventilation, including non-invasive modalities such as high flow nasal cannula and BiPAP and oxygen therapy.Measure: Evaluate the effect of intravenous L-Citrulline compared to placebo as measured by the total length of all mechanical ventilation Time: Dat 1 through Day 12
Description: To evaluate the effect of intravenous L-Citrulline compared to placebo on Hospital all-cause mortalityMeasure: Evaluate the Effect of IV L-Citrulline to Placebo for Hospital all cause mortality Time: Day 1 through day 12
Description: To evaluate the effect of intravenous L-Citrulline compared to placebo on lengths of ICU and hospital stayMeasure: Evaluate the Effect of IV L-Citrulline to Placebo on length of ICU and Hospital Stay Time: Day 1 through Day 12 (DC)
Description: To evaluate overall difference in intubation ratesMeasure: Evaluate overall difference in intubation rates Time: Day 1 to Day 10
Description: To evaluate overall duration of mechanical ventilation from consent and post-infusionMeasure: Evaluate overall duration of mechanical ventilation from consent and post-infusion Time: Day 1 through day 10
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports